Jon M. Wigginton

33.9k citations

100 papers · 3.5k indexed · h-index 32

Impact in

Immunology top 1%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Immune cells in cancer
Oncology top 1%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cytokine Signaling Pathways and Interactions

Papers in

Oncology 74
- Cancer Immunotherapy and Biomarkers 48
- CAR-T cell therapy research 35
Immunology 47
- Immunotherapy and Immune Responses 28
- Immune Cell Function and Interaction 20
- T-cell and B-cell Immunology 9

Co-authors: Robert H. Wiltrout Timothy Back F. Stephen Hodi Jeffrey Subleski Jedd D. Wolchok Michael J. Brunda Patrick A. Ott Kristin L. Komschlies
Journals: Journal of Clinical Oncology (39 papers)The Journal of Immunology (11 papers)Journal for ImmunoTherapy of Cancer (9 papers)Annals of Oncology (6 papers)Blood (5 papers)
Partner nations: United States Germany Italy

In The Last Decade

Jon M. Wigginton

99 papers receiving 3.4k citations

Peers

Countries citing papers authored by Jon M. Wigginton

Since Specialization

Citations

This map shows the geographic impact of Jon M. Wigginton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jon M. Wigginton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jon M. Wigginton more than expected).

Fields of papers citing papers by Jon M. Wigginton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jon M. Wigginton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jon M. Wigginton. The network helps show where Jon M. Wigginton may publish in the future.

Co-authors

The 25 scholars most cited alongside Jon M. Wigginton, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jon M. Wigginton Line = papers co-authored together Jon M. Wigginton links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response Journal for ImmunoTherapy of Cancer ·Fernanda I. Arnaldez, Steven O’Day, Charles G. Drake, Bernard A. Fox, Bingqing Fu, Walter J. Urba, Vincenzo Montesarchio, Jeffrey S. Weber, Haiming Wei, Jon M. Wigginton, Paolo A. Ascierto	2020	68
2	Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies Blood ·Michael P. Rettig, John E. Godwin, Norbert Vey, Bernard A. Fox, Carmen Ballesteros‐Merino, Carlo Bifulco, Daner Li, Daniel Primo, Joan Ballesteros, Jichao Sun, Hélène Lelièvre, Jan Baughman, Ross La Motte‐Mohs, John Muth, Paul A. Moore, Ezio Bonvini, Jon M. Wigginton, John F. DiPersio, Jan Davidson‐Moncada	2017	10
3	Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor Cancer Immunology Research ·Margaret K. Callahan, Gregg Masters, Christine A. Pratilas, Charlotte E. Ariyan, Jessica Katz, Shigehisa Kitano, Valerie Russell, Ruth Ann Gordon, Shachi Vyas, Jianda Yuan, Ashok Gupta, Jon M. Wigginton, Neal Rosen, Taha Merghoub, Maria Jure‐Kunkel, Jedd D. Wolchok	2013	91
4	Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages Immunology ·Ilia N. Buhtoiarov, Paul M. Sondel, Jon M. Wigginton, Tatiana Buhtoiarova, Eric Yanke, David A. Mahvi, Alexander L. Rakhmilevich	2010	112
5	Immunotherapy of cancer by IL-12-based cytokine combinations Expert Opinion on Biological Therapy ·Jonathan M. Weiss, Jeffrey Subleski, Jon M. Wigginton, Robert H. Wiltrout	2007	166
6	Proteasome Inhibition to Maximize the Apoptotic Potential of Cytokine Therapy for Murine Neuroblastoma Tumors The Journal of Immunology ·Tahira Khan, Jimmy K. Stauffer, R. H. Williams, Julie A. Hixon, Rosalba Salcedo, Erin Lincoln, Timothy Back, Douglas Powell, Stephen Lockett, Alma C. Arnold, Thomas J. Sayers, Jon M. Wigginton	2006	30
7	Therapeutic Modulation of Akt Activity and Antitumor Efficacy of Interleukin-12 Against Orthotopic Murine Neuroblastoma JNCI Journal of the National Cancer Institute ·Tahira Khan, Julie A. Hixon, Jimmy K. Stauffer, Erin Lincoln, Timothy Back, Jason Brenner, Stephen Lockett, Kunio Nagashima, Douglas Powell, Jon M. Wigginton	2006	14
8	Multicolor Fluorescence-Based Approaches for Imaging Cytokine-Induced Alterations in the Neovascularization, Growth, Metastasis, and Apoptosis of Murine Neuroblastoma Tumors Journal of Immunotherapy ·Jimmy K. Stauffer, Tahira Khan, Rosalba Salcedo, Julie A. Hixon, Erin Lincoln, Timothy Back, Jon M. Wigginton	2006	7
9	Pediatric pancreatoblastoma: histopathologic and cytogenetic characterization of tumor and derived cell line Cancer Genetics and Cytogenetics ·Linda Barenboim‐Stapleton, Xuezhong Yang, Maria Tsokos, Jon M. Wigginton, Hesed Padilla‐Nash, Thomas Ried, Carol J. Thiele	2005	13
10	IL-27 Mediates Complete Regression of Orthotopic Primary and Metastatic Murine Neuroblastoma Tumors: Role for CD8+ T Cells The Journal of Immunology ·Rosalba Salcedo, Jimmy K. Stauffer, Erin Lincoln, Timothy Back, Julie A. Hixon, Cynthia T. Hahn, Kimberly Shafer-Weaver, Anatoli Malyguine, Robert Kastelein, Jon M. Wigginton	2004	132
11	Synergistic Anti-Tumor Responses After Administration of Agonistic Antibodies to CD40 and IL-2: Coordination of Dendritic and CD8+ Cell Responses The Journal of Immunology ·William J. Murphy, (unknown), Timothy Back, Julie A. Hixon, Jeff Subleski, Naoko Seki, Jon M. Wigginton, Susan E. Wilson, Bruce R. Blazar, Anatoli Malyguine, Thomas J. Sayers, Robert H. Wiltrout	2003	84
12	Synergistic Engagement of an Ineffective Endogenous Anti-Tumor Immune Response and Induction of IFN-γ and Fas-Ligand-Dependent Tumor Eradication by Combined Administration of IL-18 and IL-2 The Journal of Immunology ·Jon M. Wigginton, Jong‐Keuk Lee, T A Wiltrout, W. Gregory Alvord, Julie A. Hixon, Jeffrey Subleski, Timothy Back, Robert H. Wiltrout	2002	60
13	IL-12/IL-2 combination cytokine therapy for solid tumours: translation from bench to bedside Expert Opinion on Biological Therapy ·Robert H. Wiltrout, Jon M. Wigginton	2002	45
14	Primary Hepatocytes from Mice Treated with IL-2/IL-12 Produce T Cell Chemoattractant Activity that Is Dependent on Monokine Induced by IFN-γ (Mig) and Chemokine Responsive to γ-2 (Crg-2) The Journal of Immunology ·Jong‐Wook Park, M. Eilene Gruys, K McCormick, Jong‐Keuk Lee, Jeffrey Subleski, Jon M. Wigginton, Robert G. Fenton, Ji-Ming Wang, Robert H. Wiltrout	2001	32
15	Complete Regression of Established Spontaneous Mammary Carcinoma and the Therapeutic Prevention of Genetically Programmed Neoplastic Transition by IL-12/Pulse IL-2: Induction of Local T Cell Infiltration, Fas/Fas Ligand Gene Expression, and Mammary Epithelial Apoptosis, The Journal of Immunology ·Jon M. Wigginton, Jong‐Wook Park, M. Eilene Gruys, Howard A. Young, Cheryl L. Jorcyk, Timothy Back, Michael J. Brunda, Robert M. Strieter, Jerrold M. Ward, Jeffrey E. Green, Robert H. Wiltrout	2001	42
16	IFN-γ-Dependent Delay of In Vivo Tumor Progression by Fas Overexpression on Murine Renal Cancer Cells The Journal of Immunology ·Jong‐Keuk Lee, Thomas J. Sayers, Alan D. Brooks, Timothy Back, Howard A. Young, Kristin L. Komschlies, Jon M. Wigginton, Robert H. Wiltrout	2000	61
17	Recruitment of Hepatic NK Cells by IL-12 Is Dependent on IFN-γ and VCAM-1 and Is Rapidly Down-Regulated by a Mechanism Involving T Cells and Expression of Fas The Journal of Immunology ·William E. Fogler, K Völker, Morihiro Watanabe, Jon M. Wigginton, Philip G. Roessler, Michael J. Brunda, John R. Ortaldo, Robert H. Wiltrout	1998	37
18	Administration of Interleukin 12 With Pulse Interleukin 2 and the Rapid and Complete Eradication of Murine Renal Carcinoma JNCI Journal of the National Cancer Institute ·Jon M. Wigginton, Kristin L. Komschlies, Timothy Back, Jeferson Luís Franco, Michael J. Brunda, Robert H. Wiltrout	1996	135
19	Evaluation of the Antitumor Activity of the Interleukin‐12/Pulse Interleukin‐2 Combinationa Annals of the New York Academy of Sciences ·Jon M. Wigginton, Kristin L. Komschlies, Jeffrey E. Green, George W. Cox, Cheryl L. Jorcyk, Timothy Back, José Luis Franco, Michael J. Brunda, Robert H. Wiltrout	1996	9
20	The potential role of serum ferritin in the pathogenesis of acquired immune deficiency syndrome (AIDS) Medical Hypotheses ·Jon M. Wigginton	1989	6

About Jon M. Wigginton

Jon M. Wigginton is a scholar working on Oncology, Immunology, Biotechnology, Hematology and Cancer Research, having authored 100 papers that have together received 3.5k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (48 papers), CAR-T cell therapy research (35 papers), Immunotherapy and Immune Responses (28 papers), Immune Cell Function and Interaction (20 papers), Monoclonal and Polyclonal Antibodies Research (13 papers), Cancer Research and Treatments (9 papers), T-cell and B-cell Immunology (9 papers) and Cancer Genomics and Diagnostics (8 papers). The work is most often cited by research in Immunology (2.0k citations), Oncology (2.1k citations), Cancer Research (290 citations), Biotechnology (130 citations) and Hematology (152 citations). Jon M. Wigginton has collaborated with scholars based in United States, Germany and Italy. Frequent co-authors include Robert H. Wiltrout, Timothy Back, F. Stephen Hodi, Jeffrey Subleski, Jedd D. Wolchok, Michael J. Brunda, Patrick A. Ott, Kristin L. Komschlies, Howard L. Kaufman and Jonathan M. Weiss. Their work appears in journals such as Journal of Clinical Oncology, The Journal of Immunology, Journal for ImmunoTherapy of Cancer, Annals of Oncology and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact